Cargando…
Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding
Mutations enhancing the kinase activity of leucine-rich repeat kinase-2 (LRRK2) cause Parkinson's disease (PD) and therapies that reduce LRRK2 kinase activity are being tested in clinical trials. Numerous rare variants of unknown clinical significance have been reported, but how the vast majori...
Autores principales: | Kalogeropulou, Alexia F., Purlyte, Elena, Tonelli, Francesca, Lange, Sven M., Wightman, Melanie, Prescott, Alan R., Padmanabhan, Shalini, Sammler, Esther, Alessi, Dario R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472821/ https://www.ncbi.nlm.nih.gov/pubmed/35950872 http://dx.doi.org/10.1042/BCJ20220161 |
Ejemplares similares
-
Endogenous Rab29 does not impact basal or stimulated LRRK2 pathway activity
por: Kalogeropulou, Alexia F., et al.
Publicado: (2020) -
Development of a multiplexed targeted mass spectrometry assay for LRRK2-phosphorylated Rabs and Ser910/Ser935 biomarker sites
por: Nirujogi, Raja S., et al.
Publicado: (2021) -
Deciphering the LRRK code: LRRK1 and LRRK2 phosphorylate distinct Rab proteins and are regulated by diverse mechanisms
por: Malik, Asad U., et al.
Publicado: (2021) -
Impact of Type II LRRK2 inhibitors on signaling and mitophagy
por: Tasegian, Anna, et al.
Publicado: (2021) -
Rab29 activation of the Parkinson's disease‐associated LRRK2 kinase
por: Purlyte, Elena, et al.
Publicado: (2017)